Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1998-9-15
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0028-4793
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
10
|
pubmed:volume |
339
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
774-5
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9742033-Colorectal Neoplasms,
pubmed-meshheading:9742033-Cost-Benefit Analysis,
pubmed-meshheading:9742033-Humans,
pubmed-meshheading:9742033-Mass Screening,
pubmed-meshheading:9742033-Occult Blood,
pubmed-meshheading:9742033-Patient Compliance,
pubmed-meshheading:9742033-Sensitivity and Specificity
|
pubmed:year |
1998
|
pubmed:articleTitle |
Role of fecal occult-blood testing.
|
pubmed:publicationType |
Letter
|